| Primary |
| Myelofibrosis |
81.0% |
| Polycythaemia Vera |
4.0% |
| Myeloproliferative Disorder |
2.2% |
| Splenomegaly |
1.9% |
| Myelodysplastic Syndrome |
1.6% |
| Pain |
1.6% |
| Supplementation Therapy |
1.3% |
| Essential Thrombocythaemia |
1.1% |
| Blood Disorder |
0.8% |
| Lymphatic Disorder |
0.5% |
| Anaemia |
0.4% |
| Budd-chiari Syndrome |
0.4% |
| Chronic Myeloid Leukaemia |
0.4% |
| Myeloid Metaplasia |
0.4% |
| Constipation |
0.4% |
| Hypertension |
0.4% |
| Insomnia |
0.4% |
| Neoplasm Malignant |
0.4% |
| Polycythaemia |
0.4% |
| Product Used For Unknown Indication |
0.4% |
|
| Death |
39.6% |
| Hospitalisation |
13.3% |
| Pneumonia |
6.6% |
| Thrombocytopenia |
4.9% |
| Platelet Count Decreased |
4.6% |
| Haemoglobin Decreased |
2.9% |
| Splenomegaly |
2.8% |
| Weight Increased |
2.6% |
| White Blood Cell Count Increased |
2.3% |
| White Blood Cell Count Decreased |
2.1% |
| Disease Progression |
2.0% |
| Epistaxis |
2.0% |
| Fall |
2.0% |
| Vomiting |
2.0% |
| Acute Myeloid Leukaemia |
1.8% |
| Acute Leukaemia |
1.7% |
| Diarrhoea |
1.7% |
| Fatigue |
1.7% |
| Pancytopenia |
1.7% |
| Weight Decreased |
1.7% |
|
| Secondary |
| Myelofibrosis |
64.7% |
| Polycythaemia Vera |
5.9% |
| Product Used For Unknown Indication |
5.3% |
| Myeloproliferative Disorder |
3.6% |
| Splenomegaly |
3.3% |
| Anaemia |
2.2% |
| Pain |
2.0% |
| Budd-chiari Syndrome |
1.6% |
| Myelodysplastic Syndrome |
1.4% |
| Essential Thrombocythaemia |
1.2% |
| Myeloid Metaplasia |
1.2% |
| Supplementation Therapy |
1.2% |
| Fluid Retention |
1.1% |
| Antibiotic Prophylaxis |
0.8% |
| Atrial Fibrillation |
0.8% |
| Fluid Overload |
0.8% |
| Gout |
0.8% |
| Thrombosis |
0.8% |
| Anaemia Of Chronic Disease |
0.6% |
| Antidepressant Therapy |
0.6% |
|
| Thrombocytopenia |
16.7% |
| Weight Increased |
8.7% |
| Platelet Count Decreased |
8.3% |
| Splenomegaly |
8.3% |
| White Blood Cell Count Decreased |
7.2% |
| Death |
6.4% |
| Hospitalisation |
6.1% |
| White Blood Cell Count Increased |
5.7% |
| Pancytopenia |
4.2% |
| Pneumonia |
3.8% |
| Vomiting |
3.8% |
| Fatigue |
3.4% |
| Haemoglobin Decreased |
3.0% |
| Anaemia |
2.7% |
| Somnolence |
2.3% |
| Weight Decreased |
2.3% |
| Epistaxis |
1.9% |
| Pyrexia |
1.9% |
| Rash |
1.9% |
| Headache |
1.5% |
|
| Concomitant |
| Product Used For Unknown Indication |
32.1% |
| Drug Use For Unknown Indication |
25.0% |
| Myelofibrosis |
7.1% |
| Myelodysplastic Syndrome |
5.4% |
| Chronic Myelogenous Leukemia |
3.6% |
| Chronic Myelomonocytic Leukaemia |
3.6% |
| Diarrhea |
3.6% |
| Hypertension |
3.6% |
| Mds |
3.6% |
| Anemia |
1.8% |
| Anticoagulant Therapy |
1.8% |
| Diabetes Mellitus |
1.8% |
| Osteoporosis |
1.8% |
| Pain |
1.8% |
| Paroxysmal Nocturnal Haemoglobinuria |
1.8% |
| Spasms |
1.8% |
|
| Myelodysplastic Syndrome |
22.2% |
| Right Ventricular Failure |
22.2% |
| Inappropriate Antidiuretic Hormone Secretion |
11.1% |
| Myelofibrosis |
11.1% |
| Pain In Extremity |
11.1% |
| Pulmonary Hypertension |
11.1% |
| Treatment Failure |
11.1% |
|
